Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05043090 · ClinicalTrials.gov registry record · Phase 3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
A Phase 3 study of Papillary Renal Cell Carcinoma, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT05043090: Active Phase 3 study of Papillary Renal Cell Carcinoma, sponsored by AstraZeneca.
NCT05043090 is a Phase 3 study of Papillary Renal Cell Carcinoma that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 148 participants, below the 229-participant average among 8 other Papillary Renal Cell Carcinoma trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05043090, a Phase 3 study of Papillary Renal Cell Carcinoma, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).
Primary Outcome
Defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The analysis will include all randomised participants as randomised, regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression.
Conditions Studied
Interventions
- DRUG durvalumab
- DRUG savolitinib
- DRUG sunitinib
Study Locations (20)
Other
- Research Site - Buenos Aires
- Research Site - CABA
- Research Site - Ciudad Autonoma Buenos Aires
- Research Site - Ciudad Autónoma Buenos Aires
- Research Site - Córdoba
- Research Site - La Plata
- Research Site - Rosario
- Research Site - San Miguel de Tucumán
- Research Site - Box Hill
- Research Site - Macquarie University
- Research Site - St Leonards
- Research Site - Belo Horizonte
- Research Site - Brasília
- Research Site - Cachoeiro de Itapemirim
- Research Site - Criciúma
- Research Site - Curitiba
- Research Site - Florianópolis
- Research Site - Fortaleza
Massachusetts
- Research Site - Boston
New York
- Research Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2025-10-30 |
| Phase | Phase 3 |
What the registry record for NCT05043090 still lists
NCT05043090 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 229-participant average among 8 other Papillary Renal Cell Carcinoma trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Papillary Renal Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which durvalumab is the first listed.
NCT05043090 names 20 study sites across 3 states, led by Other, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT05043090 about?
NCT05043090 is a clinical study titled "Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC". A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell Carcinoma).
What is the current status of trial NCT05043090?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2021-10-28. Estimated completion is 2025-10-30.
What conditions does trial NCT05043090 study?
This clinical trial studies the following conditions: Papillary Renal Cell Carcinoma.
What interventions are being tested in trial NCT05043090?
The interventions under investigation include: durvalumab (DRUG), savolitinib (DRUG), sunitinib (DRUG).
Who is sponsoring clinical trial NCT05043090?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05043090 being conducted?
This trial has 20 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillary Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05043090's enrollment target sits among peer trials
148 4th of 8 higher than 5 of 8 other Papillary Renal Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Papillary Renal Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy
RECRUITING · NA
-
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
RECRUITING · Phase 2
-
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
ACTIVE NOT RECRUITING
-
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
ACTIVE NOT RECRUITING · Phase 2
-
Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI